Trastuzumab deruxtecan in non-breast solid tumors: Expanding indications, efficacy, and future directions

Key Points

• Trastuzumab deruxtecan shows efficacy in treating solid tumors beyond breast cancer, enhancing therapeutic options.
• Clinical outcomes indicate improved patient response rates when trastuzumab deruxtecan is used for specific tumor types, particularly those with certain biomarkers.
• Analysis of treatment pathways highlights the role of trastuzumab deruxtecan in targeted therapy, showcasing its unique mechanism of action against cancer cells.
• Increasing evidence supports the need for expanded indications of trastuzumab deruxtecan, suggesting further investigation in clinical settings.